NCAM/CD56 Antibody (RNL-1): sc-53007

NCAM Antibody (RNL-1) is a mouse monoclonal IgG1 kappa light chain antibody specifically engineered to recognize Neural Cell Adhesion Molecule (NCAM), also known as CD56 or NCAM1, a vital cell surface glycoprotein involved in mediating cell-cell interactions crucial for neural development and synaptic plasticity. NCAM is characterized by its immunoglobulin-like domains and fibronectin type III repeats, which facilitate both homophilic and heterophilic binding, thereby playing an essential role in cellular adhesion, migration, and signal transduction within the nervous system. Anti-NCAM antibody (RNL-1) effectively detects multiple NCAM isoforms, including NCAM120, NCAM140, and secreted NCAM, across mouse, rat, and human species using techniques such as western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). Raised against the NCI-H82 small cell lung cancer cell line, NCAM (RNL-1) antibody is particularly valuable for identifying neuroectodermally derived tumors like neuroblastoma, medulloblastoma, astrocytoma, and retinoblastoma, underscoring NCAM1′s significance in tumor biology. Additionally, NCAM monoclonal antibody (RNL-1) facilitates the study of NCAM′s structural variants resulting from alternative splicing and polyadenylation, enhancing research on embryogenesis and neural tissue maintenance. Available for various applications, anti-NCAM antibody (RNL-1) supports detailed analysis of NCAM′s role in both normal physiology and disease states. NCAM (RNL-1) monoclonal antibody is recommended for advancing our understanding of neural cell adhesion mechanisms and the pathological implications of NCAM dysregulation.

The preferred NCAM/CD56 antibody is NCAM/CD56 Antibody (ERIC 1): sc-106.